IRBs: Ethics, Context and Interpretations

IRB:道德、背景和解释

基本信息

项目摘要

DESCRIPTION (provided by applicant): I plan to write a book exploring several crucial & related issues concerning Institutional Review Boards (IRBs), which have increasingly been facing critical challenges, problems & dilemmas. Established in 1974, following the Tuskegee scandal, to protect human subjects, IRBs have been shown to be inconsistent & discrepant, applying standards differently, & are facing mounting challenges (e.g., concerning clinical trials). Ideally, IRB review can abet research, protecting subjects, & avoiding unnecessary harms, fostering trust of communities & the public. Yet critics argue that IRBs can delay or impede recruitment & some kinds of research, hampering attainment of important knowledge, thus antagonizing Principal Investigators (PIs) who may then try to "bend the rules". Unethical practices can cause harms (e.g., death of subjects), & distrust, especially in vulnerable communities. These issues are particularly important with HIV, & other rapidly evolving areas (e.g., genetics), & in the developing world, where US-funded research is increasing. Recently, IRBs have been receiving more scholarly attention, but most of this work has been theoretical. Interviews I have conducted suggest that IRBs are deeply embedded in intricate social, regulatory, political, institutional, historical & scientific contexts. A few quantitative studies have examined logistical issues about IRBs (e.g., composition), but almost no qualitative data have explored these complex issues. No book has systematically examined how IRBs themselves grapple with the complex demands, conflicts, & social & institutional pressures they confront. The specific aims of this book are to provide a framework for examining several issues, e.g., 1) conflicts IRBs face with PIs, 2) variations between IRBs, & 3) suggestions for reform. To understand these phenomena, it is essential to grasp how IRBs function today: the contents & contexts of decisions. I will explore several key questions: 1) What problems do IRBs see themselves as facing regarding the contents of decisions? (e.g., what & how they weigh individual & social risks & benefits, competing ethical principles, & varying interpretations & applications of principles & regulations)? 2) What challenges do IRBs face regarding the contexts of decisions (i.e., shifting social, economic, institutional & scientific contexts of research, e.g., more multi-site studies, industry-funded trials, university-industry collaborations, managed care, & research "scandals")? 3) How do IRBs view & address these problems & criticisms (e.g., costs to PIs of IRB review, & inconsistencies), & possible changes (e.g., centralized IRBs, or appeals processes)? 4) What are the implications of the above for improving education (e.g., of IRBs, PIs, & policy-makers), IRB practices & policies, & future research in this area? I have interviewed in-depth chairs & members from over 60 IRBs, & other key stakeholders (e.g., PIs & research staff, & study subjects), mostly in the US, & to a lesser extent in the developing world. The book, which my editor at Oxford University Press is extremely interesting in publishing, will focus on IRBs in the US, though exploring these issues, though to a lesser degree, in the developing world as well.
描述(由申请人提供):

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ROBERT L KLITZMAN其他文献

ROBERT L KLITZMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ROBERT L KLITZMAN', 18)}}的其他基金

Ethics and Policy Core
道德和政策核心
  • 批准号:
    8015618
  • 财政年份:
    2010
  • 资助金额:
    $ 7.99万
  • 项目类别:
IRBs: Ethics, Context and Interpretations
IRB:道德、背景和解释
  • 批准号:
    8144256
  • 财政年份:
    2009
  • 资助金额:
    $ 7.99万
  • 项目类别:
Ethics and Policy Core
道德和政策核心
  • 批准号:
    7900718
  • 财政年份:
    2009
  • 资助金额:
    $ 7.99万
  • 项目类别:
IRBs: Ethics, Context and Interpretations
IRB:道德、背景和解释
  • 批准号:
    7620223
  • 财政年份:
    2009
  • 资助金额:
    $ 7.99万
  • 项目类别:
Ethics and Policy Core
道德和政策核心
  • 批准号:
    7343533
  • 财政年份:
    2008
  • 资助金额:
    $ 7.99万
  • 项目类别:
Views and Approaches Toward Research Integrity Among IRBs
IRB 对研究诚信的看法和方法
  • 批准号:
    7124890
  • 财政年份:
    2006
  • 资助金额:
    $ 7.99万
  • 项目类别:
Views and Approaches Toward Research Integrity Among IRBs
IRB 对研究诚信的看法和方法
  • 批准号:
    7287439
  • 财政年份:
    2006
  • 资助金额:
    $ 7.99万
  • 项目类别:
Views of Privacy of Genetic Information
对遗传信息隐私的看法
  • 批准号:
    6620621
  • 财政年份:
    2002
  • 资助金额:
    $ 7.99万
  • 项目类别:
Views of Privacy of Genetic Information
对遗传信息隐私的看法
  • 批准号:
    6419830
  • 财政年份:
    2002
  • 资助金额:
    $ 7.99万
  • 项目类别:
Views of Privacy of Genetic Information
对遗传信息隐私的看法
  • 批准号:
    6849753
  • 财政年份:
    2002
  • 资助金额:
    $ 7.99万
  • 项目类别:

相似海外基金

Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10707830
  • 财政年份:
    2023
  • 资助金额:
    $ 7.99万
  • 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
  • 批准号:
    479728
  • 财政年份:
    2023
  • 资助金额:
    $ 7.99万
  • 项目类别:
    Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
  • 批准号:
    10884567
  • 财政年份:
    2023
  • 资助金额:
    $ 7.99万
  • 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
  • 批准号:
    10751964
  • 财政年份:
    2023
  • 资助金额:
    $ 7.99万
  • 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
  • 批准号:
    486321
  • 财政年份:
    2022
  • 资助金额:
    $ 7.99万
  • 项目类别:
    Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10676786
  • 财政年份:
    2022
  • 资助金额:
    $ 7.99万
  • 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10440970
  • 财政年份:
    2022
  • 资助金额:
    $ 7.99万
  • 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
  • 批准号:
    10642998
  • 财政年份:
    2022
  • 资助金额:
    $ 7.99万
  • 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10482465
  • 财政年份:
    2022
  • 资助金额:
    $ 7.99万
  • 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
  • 批准号:
    10191053
  • 财政年份:
    2020
  • 资助金额:
    $ 7.99万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了